STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,084,836 | -77.6% | 275,339 | -39.5% | 0.00% | -50.0% |
Q2 2023 | $4,837,872 | +346452.4% | 455,115 | +171.7% | 0.00% | +100.0% |
Q1 2023 | $1,396 | -63.9% | 167,529 | -60.0% | 0.00% | -50.0% |
Q4 2022 | $3,869 | -100.0% | 419,179 | -36.1% | 0.00% | -60.0% |
Q3 2022 | $8,422,000 | -32.9% | 655,949 | -30.9% | 0.01% | -37.5% |
Q2 2022 | $12,545,000 | +39.2% | 949,658 | +121.9% | 0.01% | +60.0% |
Q1 2022 | $9,009,000 | +150.9% | 427,997 | +186.0% | 0.01% | +150.0% |
Q4 2021 | $3,590,000 | +157.3% | 149,625 | +172.9% | 0.00% | +100.0% |
Q3 2021 | $1,395,000 | -54.8% | 54,825 | -31.0% | 0.00% | -50.0% |
Q1 2021 | $3,087,000 | -49.0% | 79,477 | -68.7% | 0.00% | -75.0% |
Q2 2020 | $6,058,000 | +133.1% | 254,229 | +124.0% | 0.01% | +33.3% |
Q1 2020 | $2,599,000 | -71.5% | 113,493 | -64.8% | 0.01% | -45.5% |
Q4 2019 | $9,130,000 | -39.1% | 322,381 | -53.8% | 0.01% | -54.2% |
Q3 2019 | $14,995,000 | -7.0% | 697,811 | +26.2% | 0.02% | 0.0% |
Q2 2019 | $16,123,000 | – | 552,730 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |